Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc., announced that it is developing new Quality Management solutions, in collaboration with Accuray, for the company’s Radixact System with Synchrony®, which enables real-time, personalized adaptive radiation therapy. Initial innovations from the collaboration will be featured in the Sun Nuclear booth (980) at the ASTRO Annual Meeting, October 23-25, 2022, in San Antonio, Texas.
The Enhanced Dynamic Platform, the first release to come from the expanded partnership, is a next-generation design of the Dynamic Platform from CIRS, now part of Sun Nuclear. It enables movement of compatible phantoms with sub-millimeter accuracy and reproducibility, easing quality assurance (QA) and boosting clinical confidence for advanced tumor treatments.
Also Read: RhythMedix Expands Monitoring Capabilities of Its RhythmStar System
The Enhanced Dynamic Platform allows for precisely controlled inferior-superior motion and features the ability to create an inclined plane for compatible phantom motion in the posterior-anterior direction. An independently controlled smaller platform provides surrogate chest wall motion. CIRS Motion Control Software enables different cycles, amplitudes, and waveforms – as well as the import of patient-specific respiratory waveforms.
The Enhanced Dynamic Platform integrates with the Sun Nuclear Tomo-Phantom HE (“Cheese Phantom”), supporting the Accuray acceptance tests procedure (ATP), as handled by the legacy Dynamic Platform.
Also on display in the Sun Nuclear ASTRO booth will be the work-in-progress MotionCHECK 3D System. Designed to support the tumor tracking capabilities of Synchrony, MotionCHECK 3D is intended to integrate the Enhanced Dynamic Platform with the ArcCHECK array, the benchmark for 3D pre-treatment patient QA in radiation therapy.
The Radixact Treatment Delivery System provides a fully-integrated platform for treatment planning, data management and treatment delivery, and supports multiple precise treatment techniques, including motion synchronized radiation therapy. For these delivery types, Accuray’s Synchrony real-time motion synchronization technology enables clinics to treat patients without any ITV (Internal Target Volume), with no gating, and with automated tumor tracking. Unique to Synchrony is a sophisticated AI-based predictive modeling of the target position that brings the beam steering in synch with the target motion.
“We have collaborated often with Sun Nuclear on QA solutions specific to the technologies that Accuray produces. Now with their expanded motion management portfolio, we are excited to work with them again on a solution for our Radixact® System with Synchrony® and look forward to collaborating on other motion management QA solutions in the future,” said Dylan Casey, Ph.D., Senior Director, Medical Physics and Systems Analysis at Accuray Incorporated.